Media

Media Release, Wednesday 25 September 2019, Melbourne, Australia – Australia’s largest medicinal cannabis distributor and clinical research organisation, Cannvalate, has signed a memorandum of understanding for conducting novel cannabinoid research with Israeli specialist cannabis research firm Cannbit (TASE:CNBT).

Cannbit, is a $70M listed company on the Tel Aviv Stock Exchange, and the firm’s head researcher Professor Raphael Mechoulam, is well known as the ‘father of medicinal cannabis’ for his original pioneering works on developing cannabis as a medicine.

“This MOU cements Cannvalate’s, and also Australia’s, position as the global centre for medicinal cannabis research.” said Dr Sud Agarwal, CEO and cofounder of Cannvalate.

“We feel totally privileged to be able to conduct cannabinoid clinical research in conjunction with Cannbit and Professor Mechoulam.”

# ENDS #

Media Contact for Cannvalate | The PR Hub Samantha Dybac, Managing Director
+61 411 251 373 | samantha@theprhub.com.au

Available for Interview:

Dr Sud Agarwal, CEO and cofounder, Cannvalate

www.cannvalate.com.au

Download Cannvalate high res Imagery

Dr Sud Agarwal https://bit.ly/2Ed5y7S ———-

About Cannvalate

Cannvalate is Australia’s largest business-to-business services company helping Licensed Producers of medicinal cannabis fast track their growth into the Australian market. As
Their four key services include:

1. ACMA (Australian Cannabis Market Access) – Australia’s largest network of medicinal cannabis prescribing clinics, consisting of more than 1,000 referring healthcare professionals and 600 affiliated pharmacies spanning all states of Australia. Cannvalate prescriptions currently account for over 30% of the Australian market, which has seen the number of total monthly prescriptions increase by over 800% in the last twelve months.

2. Medicinal Cannabis Research – fast-tracked clinical trials to enhance standing with medical prescribers

3. CannaFarm – ready to grow, turnkey cultivation hubs with all licenses/permits provided

4. Compliance as a service – outsourced license applications for Import/ Export, Cultivation, Research, Manufacturing, Wholesale

Dr Sud Agarwal bio

Dr Sud Agarwal is an internationally recognised key opinion leader in the clinical use of medicinal cannabis and is regularly invited as a keynote to key industry and pharmaceutical events including the World Cannabis Conference and the Australian Medicinal Cannabis Conference.

Dr Agarwal is the co-founder and chief executive officer of Cannvalate, Australia’s first medically backed, medicinal cannabis company, focused on providing a seamless entry for global licensed producers of medicinal cannabis into the Australian market.

He was also recently appointed by Impression Healthcare (ASX:IHL) as chief medical officer and as a non-executive board director. Dr Agarwal’s appointment will support Impression Healthcare’s focus on streamlining current and future medicinal cannabis clinical trials along with product commercialisation strategies, including investor and stakeholder relations.

Dr Agarwal received his medical qualifications in the United Kingdom before immigrating to Australia in 2001. He has since commercialised, scaled and successfully exited three healthcare businesses and has a track record for seeing business opportunities at their earliest stage, and building high performing teams.

Dr Agarwal is also an experienced property developer who has completed 7 projects comprising residential, commercial and mixed-use projects. As the founder and director of Sterling Property Group, he has proven his ability to achieve excellent design and planning results, manage construction projects and deliver multi-faceted built form outcomes on time, under cost and with superior quality.

A rare combination of extensive medical experience, commercialisation success in several healthcare businesses and a proven track record in property development, positions Dr Agarwal perfectly to lead Cannvalate.